Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms

European Neurology

Volumn 52, Issue 1, 2004, Pages 50-56

  Diener, H C ^a   Eikermann, A ^a   Gessner, U ^b   Gobel H ^c   Haag, G ^d   Lange, R ^e   May, A ^f   Muller Schwefe G ^g   Voelker, M ^e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Bayer Vital GmbH   (Germany)

^c Kiel Pain Clinic   (Germany)

^d Michael Balint Clinic   (Germany)

^e BAYER AG   (Germany)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g Interdisciplinary Pain Relief Centre   (Germany)

Author keywords

Acetylsalicylic acid; Migraine, accompanying symptoms; Phonophobia; Photophobia; Sumatriptan

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; SUMATRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE DRUG DOSE; TABLET FORMULATION;

ADOLESCENT; ADULT; AGED; ASPIRIN; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SUMATRIPTAN; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 4043051048     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079544     Document Type: Article

References (21)

1. Goadsby PJ, Lipton RB, Ferrari MD: Migraine - Current understanding and treatment. N Engl J Med 2002;346:257-270.
2. Oldman AD, Smith LA, McQuay HJ, Moore RA: Pharmacological treatments for acute migraine: Quantitative systemic review. Pain 2002;97:247-257.
3. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB: Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a metaanalysis of 53 trials. Cephalalgia 2002;22:633-658.
4. Pfaffenrath V, Scherzer S: Analgesics and NSAIDs in the treatment of acute migraine attacks. Cephalalgia 1995;15(suppl):14-20.
5. Limmroth V, Katsarava Z, Diener HC: Acetylsalicylic acid in the treatment of headache. Cephalalgia 1999;19:545-551.
6. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewart RG, Schoenen J, Chazot G: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-926.
7. Lipton RB, Baggish JE, Stewart WF, Codispoti JR, Fu M: Efficacy and safety of acetaminophen in the nonprescripton treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000;160:3486-3492.
8. Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF, Wilkes K, Furey SA, Subramanian T, Cooper SA: Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 2000;20:233-243.
9. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: A multicentre double-blind placebo-controlled study. Cephalalgia 1994;14:297-300.
10. Lange R, Schwarz JA, Hohn M: Acetylsalicylic acid effervescent 1,000 mg (Aspirin®) in acute migraine attacks: A multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000;20:663-667.
11. Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Göbel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M: Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia, in press.
12. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
13. Milton KA, Kleinermans D, Scott N, Cooper JDH: The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. Int J Pharm Med 2001;15:21-26.
14. Lehmacher W, Wassmer G: Adaptive sample size calculations in group sequential trials. Biometrics 1999;55:1286-1290.
15. Casagrande JT, Pike MC, Smith PG: An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34:483-486.
16. Pocock SJ, Geller NL, Tsiatis AA: The analysis of multiple endpoints in clinical trials. Biometrics 1987;43:487-498.
17. Marcus R, Peritz KR, Gabriel KR: On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-660.
18. Geraud G, Compagnon A, Rossi A, on behalf of the COZAM Study Group: Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: A double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98.
19. Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser M, and the Bi-Profenid Migraine Study Group: Efficacy of oral ketoprofen in acute migraine: A double-blind randomized clinical trial. Neurology 2002;58:1660-1665.
20. The Diclofenac-K/Sumatriptan Migraine Study Group: Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999;19:232-240.
21. Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, Vapaatalo H, Eskerod O: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998;38:201-207.